A peptide drug targeting SASH1-PKM2 interaction promotes recovery of traumatic brain injury in mice.
Level 5 - mechanism / opinion, no new human data
Preclinical laboratory study using cell cultures and a mouse model without human data.
PubMed 41690666 · doi:10.1016/j.brainres.2026.150206
What was done
Researchers investigated the interaction between the scaffold protein SASH1 and PKM2 in astrocytes and tested a therapeutic peptide in a mouse model of traumatic brain injury (TBI). In vitro, they evaluated PKM2 nuclear translocation, glucose uptake, lactate release, and mRNA expression of Glut1 and lactate dehydrogenase A (LDHA) following SASH1 silencing. In vivo, they administered a designed peptide targeting the SASH1-PKM2 interaction to TBI-model mice to evaluate astrocytic activation and wound healing.
What was found
The abstract reports qualitative findings without exact numerical values, effect sizes, or confidence intervals. SASH1 was found to interact with PKM2. Silencing SASH1 caused nuclear accumulation of PKM2, increased glucose uptake, elevated lactate release, and upregulated Glut1 and LDHA mRNA expression. In mice with TBI, administration of the peptide blocking the SASH1-PKM2 interaction significantly reduced astrocytic activation and enhanced tissue wound healing.
Why it matters
The study identifies the SASH1-PKM2 signaling axis as a regulator of astrocyte metabolism and activation after brain trauma. It suggests that disrupting this interaction with a targeted peptide may reduce glial scarring and support neural tissue repair.
Limits
The abstract provides no exact sample sizes, dosage details, behavioral functional metrics, or quantitative data. As an early-stage preclinical study in mice and cell culture, findings cannot be directly extrapolated to human traumatic brain injury without extensive further testing.
Cited by
- supports Traumatic brain injury disrupts the ability of astrocytes to produce lactate in the brain.